Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
about
The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary DysenteryVaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirusStructures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibodyA piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1Shigella: A Highly Virulent and Elusive PathogenImmune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.Development of Vi conjugate - a new generation of typhoid vaccine.Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.Shigella flexneri infection in a newly acquired rhesus macaque (Macaca mulatta)O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2aO-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.Particle-based platforms for malaria vaccines.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Progress and pitfalls in Shigella vaccine research.Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugatesCarbohydrate vaccines: developing sweet solutions to sticky situations?Shigella Vaccine Development: Finding the Path of Least Resistance.An update on vaccines against Shigella.The human intestinal IgA response; burning questions.Recent progress towards development of a Shigella vaccine.Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta)A scalable method for O-antigen purification applied to various Salmonella serovars.Reaching a consensus on management practices and vaccine development targets for mitigation of infectious diarrhoea among deployed US military forces.Future vaccine development at NICHD.Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.
P2860
Q26825840-783F65AF-ADAF-4EFC-AD7B-CC189768BDD6Q26995690-1CB1B3DE-5168-4CBB-BFB8-2816FB56182BQ27651173-F5F866B4-BF45-46D1-BBA7-E5E0699B20FBQ33678906-09CB6E13-B226-4B90-BEF2-7756FB095E49Q34019305-BF7F4676-5238-4579-9B4F-722A499A53BFQ34334260-9E1D08E1-A311-453E-8D05-1C256E6ED28AQ34380025-C1D4AF19-BD5B-4305-9157-25086530A75BQ34394744-DE6E9626-FA29-48F4-A28B-26C4BA47DCC2Q35653427-E1F6868B-3658-4298-AFE9-EA44B7F5A8DBQ35828313-D1C98812-8744-4FD5-AE00-26A0F6C1AB55Q35844488-5D4C8DB7-A2AE-4DCC-81EF-AB4AA73A84DCQ35887055-5B058ACD-AE76-4CD6-9688-F7F9C6773EFFQ36128243-8ED12587-712E-4D13-B440-460E4D8FA4C6Q36165265-21CD6FAD-0C10-4A5A-9612-CFA2DA32898BQ36396040-9A54B0AB-7BAE-439A-A6FB-7FAFB5CD8455Q36844719-1F5AA0E4-D4CA-4F6E-8B7E-DAD5C0F13FCBQ37105553-7F90F533-7056-40ED-BEA4-A38FB98B6100Q37194696-3A7D33B1-63C6-4B69-8AA7-7B00FA38EC18Q37426039-251906FC-80A6-4B81-8F0A-791643AED537Q37477191-CC9075BA-EE60-4358-884E-D303B61A6F47Q37668395-0EE23F43-16A3-4A52-A6A2-9268EBCE203EQ38010705-29EDD69B-64E5-4493-955D-3E74599CC01BQ38068954-F8867988-7687-4475-8B08-13DB4945E0BBQ38294092-D40BA740-8569-486D-AD6E-3023428C381CQ38538720-EAE4C8B2-4658-450F-8075-2CA784C0D1B3Q39397885-8D9E4847-8322-4706-AF5F-BD106C7283C7Q40429740-1285CA24-0B9B-417D-9E35-A685AF2E107EQ41008205-F67E3C55-A575-4EF8-91FF-C660D6EA1CB9
P2860
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Safety and immunogenicity of S ...... ne- to four-year-old children.
@en
type
label
Safety and immunogenicity of S ...... ne- to four-year-old children.
@en
prefLabel
Safety and immunogenicity of S ...... ne- to four-year-old children.
@en
P2093
P1476
Safety and immunogenicity of S ...... ne- to four-year-old children.
@en
P2093
Chiayung Chu
Efrat Harlev
Israel Shigella Study Group
John B Robbins
Joseph Shiloach
Justen H Passwell
Liat Lerner-Geva
Nahid Farzam
Reut Ramon
P304
P356
10.1097/01.INF.0000078156.03697.A5
P577
2003-08-01T00:00:00Z